240 related articles for article (PubMed ID: 10706647)
1. Second-line treatment of ovarian cancer.
Markman M; Bookman MA
Oncologist; 2000; 5(1):26-35. PubMed ID: 10706647
[TBL] [Abstract][Full Text] [Related]
2. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
3. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
4. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.
Modesitt SC; Jazaeri AA
Expert Opin Pharmacother; 2007 Oct; 8(14):2293-305. PubMed ID: 17927484
[TBL] [Abstract][Full Text] [Related]
5. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
[TBL] [Abstract][Full Text] [Related]
6. [Ovarian cancer--therapeutic options after the failure of the first line of treatment].
Jabłońska E; Chłosta M; Pawlega J
Ginekol Pol; 2004 Jan; 75(1):58-64. PubMed ID: 15112475
[TBL] [Abstract][Full Text] [Related]
7. Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Pujade-Lauraine E; Banerjee S; Pignata S
J Clin Oncol; 2019 Sep; 37(27):2437-2448. PubMed ID: 31403868
[No Abstract] [Full Text] [Related]
8. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
Harter P; Hilpert F; Mahner S; Heitz F; Pfisterer J; du Bois A
Expert Rev Anticancer Ther; 2010 Jan; 10(1):81-8. PubMed ID: 20014888
[TBL] [Abstract][Full Text] [Related]
9. Therapy for recurrent ovarian cancer.
Kuhn WC
Curr Womens Health Rep; 2003 Feb; 3(1):33-8. PubMed ID: 12521548
[TBL] [Abstract][Full Text] [Related]
10. Second-line treatment of first relapse recurrent ovarian cancer.
Chua TC; Liauw W; Robertson G; Morris DL
Aust N Z J Obstet Gynaecol; 2010 Oct; 50(5):465-71. PubMed ID: 21039382
[TBL] [Abstract][Full Text] [Related]
11. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
Patnaik A; Doyle C; Oza AM
Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
[TBL] [Abstract][Full Text] [Related]
12. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery in the management of ovarian cancer.
Schwartz PE
Oncology (Williston Park); 2008 Aug; 22(9):1025-33; discussion 1033-8, 1041, 1045. PubMed ID: 18777954
[TBL] [Abstract][Full Text] [Related]
14. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
15. Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study.
Fotopoulou C; Cho CH; Kraetschell R; Gellermann J; Wust P; Lichtenegger W; Sehouli J
Int J Hyperthermia; 2010; 26(2):118-26. PubMed ID: 20146566
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M; Khemapech N
Asian Pac J Cancer Prev; 2013; 14(12):7669-74. PubMed ID: 24460351
[TBL] [Abstract][Full Text] [Related]
17. Optimizing treatment in recurrent epithelial ovarian cancer.
Corrado G; Salutari V; Palluzzi E; Distefano MG; Scambia G; Ferrandina G
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1147-1158. PubMed ID: 29086618
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Petrillo M; Pedone Anchora L; Tortorella L; Fanfani F; Gallotta V; Pacciani M; Scambia G; Fagotti A
Gynecol Oncol; 2014 Aug; 134(2):257-61. PubMed ID: 24910451
[TBL] [Abstract][Full Text] [Related]
19. Investigational agents for epithelial ovarian cancer.
Muggia F; Kosloff R
Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
[TBL] [Abstract][Full Text] [Related]
20. Surgical management of recurrent ovarian cancer.
Leitao MM; Chi DS
Semin Oncol; 2009 Apr; 36(2):106-11. PubMed ID: 19332245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]